Fenebrutinib, Genentech’s investigational BTK inhibitor, was found to significantly reduce relapse rates compared with the approved therapy Aubagio (teriflunomide) in two Phase 3 clinical trials involving people with relapsing forms of multiple sclerosis (MS). Positive top-line results from one of those trials, FENhance 2 (NCT04586023),…
fenebrutinib
The investigational BTK inhibitor fenebrutinib was as effective as the approved therapy Ocrevus (ocrelizumab) at reducing the risk of disability progression in people with primary progressive multiple sclerosis (PPMS), meeting the main goal of a Phase 3 trial. According to fenebrutinib’s developer, Genentech, the therapy is the…
Recommended Posts
- In ‘landmark’ approval, FDA OKs Ocrevus for kids 10 and older with RRMS
- Bike MS in Texas – largest of events in US – raises over $9M for research, care
- Tampons could offer way to monitor multiple sclerosis nerve damage
- Life with MS is hard, but you don’t have to figure it out on your own
- Phase 2 pegsebrenatide trial begins dosing in progressive MS